4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME

• 4D Molecular Therapeutics outlined a strategy centered on 4D-150, an intravitreal AAV gene therapy for wet AMD, moving into a global Phase 3 program.
• Program expansion also targets diabetic macular edema, positioning 4D-150 as a potential long-duration backbone anti-VEGF therapy.
• Presentation framed the retinal vascular anti-VEGF market at about USD 16 billion in 2025E, with wet AMD plus DME at about USD 14 billion.
• Phase 2b PRISM data cited for 4D-150 at 3E10 vg/eye showed 1 mean supplemental injection through 1 year, implying ~365+ day interval.
• Pipeline update also highlighted 4D-710 for cystic fibrosis lung disease as fully funded, with 4D-725 for A1AT lung disease funded through IND.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.